Key result
Cyclodextrin inhibits AAA formation and progression via VSMC TFEB activation in preclinical models.
Why the study?
Pharmacological therapy is needed to inhibit abdominal aortic aneurysm (AAA) expansion and prevent rupture, and the role of vascular smooth muscle cell (VSMC) transcription factor EB (TFEB) in AAA development required investigation.
Does 2-hydroxypropyl-β-cyclodextrin prevent abdominal aortic aneurysm formation and progression via activation of vascular smooth muscle cell TFEB in mouse models?
Does 2-hydroxypropyl-β-cyclodextrin prevent abdominal aortic aneurysm formation and progression via activation of vascular smooth muscle cell TFEB in mouse models?
Answers are grounded in this paper and cite their sources.
Preclinical evidence identifies vascular smooth muscle cell TFEB activation via 2-hydroxypropyl-β-cyclodextrin as a potential pharmacological target to inhibit abdominal aortic aneurysm formation and progression.
BACKGROUND: Abdominal aortic aneurysm (AAA) is a severe aortic disease with a high mortality rate in the event of rupture. Pharmacological therapy is needed to inhibit AAA expansion and prevent aneurysm rupture. Transcription factor EB (TFEB), a master regulator of autophagy and lysosome biogenesis, is critical to maintain cell homeostasis. In this study, we aim to investigate the role of vascular smooth muscle cell (VSMC) TFEB in the development of AAA and establish TFEB as a novel target to treat AAA. METHODS: knockout mice and different mouse AAA models, we determined the role of VSMC TFEB and a TFEB activator in AAA in vivo. RESULTS: We found that TFEB is downregulated in both human and mouse aortic aneurysm lesions. TFEB potently inhibits apoptosis in VSMCs, and transcriptome analysis revealed that TFEB regulates apoptotic signaling pathways, especially apoptosis inhibitor B-cell lymphoma 2. B-cell lymphoma 2 is significantly upregulated by TFEB and is required for TFEB to inhibit VSMC apoptosis. We consistently observed that TFEB deficiency increases VSMC apoptosis and promotes AAA formation in different mouse AAA models. Furthermore, we demonstrated that 2-hydroxypropyl-β-cyclodextrin, a clinical agent used to enhance the solubility of drugs, activates TFEB and inhibits AAA formation and progression in mice. Last, we found that 2-hydroxypropyl-β-cyclodextrin inhibits AAA in a VSMC TFEB-dependent manner in mouse models. CONCLUSIONS: Our study demonstrated that TFEB protects against VSMC apoptosis and AAA. TFEB activation by 2-hydroxypropyl-β-cyclodextrin may be a promising therapeutic strategy for the prevention and treatment of AAA.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2020) studied Abdominal aortic aneurysm (AAA). 2-hydroxypropyl-β-cyclodextrin was evaluated on Abdominal aortic aneurysm formation and progression, and vascular smooth muscle cell apoptosis. 2-hydroxypropyl-β-cyclodextrin activates transcription factor EB (TFEB) and inhibits abdominal aortic aneurysm formation and progression in a VSMC TFEB-dependent manner in mouse models.
Synapse has enriched 10 related papers. Consider them for comparative context: